Atossa Genetics (ATOS) Posts Narrower Q2 Loss

August 12, 2016 8:13 AM EDT
Get Alerts ATOS Hot Sheet
Trade ATOS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Atossa Genetics (NASDAQ: ATOS) reported Q2 EPS of ($0.05), versus ($0.11) reported last year.

For the three months and six months ended June 30, 2016, the Company recorded a net loss of $1.7 million and $4.0 million, respectively.

Atossa's important recent developments include the following:

  • In August, 2016, Atossa Genetics Settled Litigation With Besins Healthcare, to receive Cash Payment of $1.76 Million, License Agreement Terminated
  • In June 2016, Atossa Genetics Initiated an Additional Drug Development Program with Oral Endoxifen for Patients Refractory to Tamoxifen
  • In May 2016, Atossa Genetics Announced a $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
  • In March 2016, Atossa Genetics Opened its Phase 2 Clinical Trial of Intraductal Fulvestrant Administration in Women with DCIS or Breast Cancer

For earnings history and earnings-related data on Atossa Genetics (ATOS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment